Navigation Links
Genomas Awarded US Patent for its PhyzioGenomics Platform Technology to Predict Treatment Responses
Date:9/13/2010

HARTFORD, Conn., Sept. 13 /PRNewswire/ -- Genomas®, a biomedical company advancing DNA-Guided Medicine, has been awarded US Patent 7,747,392, entitled Physiogenomic Method for Predicting Clinical Outcomes of Treatment in Patients by the US Patent and Trademark Office.

Andreas Windemuth, Ph.D., Chief Technology Officer and co-inventor in the patent stated: "The PhyzioGenomics Technology has been successfully applied to several psychiatric and diabetes drugs and to brain imaging. The technology correlates genotypes and phenotypes in patient populations to discover clinically functional variability. The PhyzioGenomics Technology integrates a biomedical engineering systems approach with genome probes and nano-arrays."

Research on the PhyzioGenomics Technology has been published in the renowned journals Annals of Biomedical Engineering, Biomedical Engineering Handbook, Clinica Chimica Acta, Clinics in Laboratory Medicine, Molecular Psychiatry, Muscle & Nerve, Personalized Medicine, Pharmacogenomics, and Schizophrenia Research.

Gualberto Ruano, M.D., Ph.D., President of Genomas and co-inventor commented: "This fundamental patent covers also the configuration of our products and pipeline, the PhyzioTypeTM Systems. This is a landmark achievement for Genomas and allows us freedom to operate in our industry sector. In an otherwise crowded genomics landscape, and in the presence of an ever more stringent yardstick on novelty versus prior art, this patent significantly increases the value of our intellectual property portfolio and differentiates our proprietary PhyzioType products."

Filed in 2006, US Patent 7,747,392 comprises 23 methods claims and 384 polymorphic DNA sequences representative of 222 key cardiometabolic and neuroendocrine genes. Beyond this patent, the Intellectual Property portfolio of Genomas encompasses 5 patent applications, 2 trademarks, and a copyright on the company's clinical informatics system.

ABOUT GENOMAS

Genomas is a biomedical company advancing DNA-Guided Medicine and personalized healthcare. The company develops revolutionary PhyzioType™ Systems for DNA-guided management and prescription of drugs used to treat mental illness and diabetes. PhyzioType Systems provide physicians with an unprecedented capability to select for each patient the safest and most effective drug to achieve treatment goals and enhance patient compliance.

The company's clinical pharmacogenetic tests and consultation service are provided through its Laboratory of Personalized Health, an accredited and licensed high-complexity molecular diagnostic center and its Personalized Health Portal, a medical informatics interface for clinician decision support. Visit www.genomas.com for more information.


'/>"/>
SOURCE Genomas
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genomas Awarded $1.4 Million NIH SBIR Grant to Develop MRI+DNA Guided Biomarker System for Mental Illness
2. Genomas and Institute of Living Among Organizers of Pharmacogenetics Symposium at 2009 Annual Meeting of the American Psychiatric Association
3. Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
4. Genomas to Present at Life Sciences & Healthcare Venture Summit
5. Connecticut State Medical Society and Genomas Co-Sponsor Forum on DNA-Guided Medicine and the Path to Personalized Health Care
6. Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax
7. Isolux Corsan Awarded a Contract for the Construction of an Ethanol Plant in Colombia
8. Laser pioneer Federico Capasso awarded Berthold Leibinger Zukunftspreis
9. San Diego Region Awarded $4 Million Workforce Development Grant to Support Expanding Biofuels Industry
10. Flad Architects Awarded Livermore Valley Open Campus Master Plan
11. Colorado State University student awarded top student prize in laser research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... Grand Bahama (PRWEB) , ... July 26, 2017 , ... ... Regenerative Medicine , which is licensed by the Bahamas’ National Stem Cell Ethics Committee ... (MBBS) from the University of the West Indies. He went on to complete residency ...
(Date:7/26/2017)... - Caprion Biosciences Inc., a world leading specialty CRO announced the ... of early stage (latent) Mycobacterium tuberculosis (Mtb) infection using state-of-the-art ... platform. ... Caprion Biosciences Inc. (CNW Group/Caprion Biosciences) ... The new data, recently published in ...
(Date:7/26/2017)... ... July 25, 2017 , ... The leading Regenerative Veterinary Medicine ... cell therapy has been used on more than 13,000 animals. VetStem was ... fatal injuries to tendons and ligaments. , In 2003 VetStem signed a worldwide ...
(Date:7/26/2017)... ... July 26, 2017 , ... Spectral ... we face every day. This unique capability combines high resolution imaging with ... manufacturers to deliver unprecedented datasets for chemical analysis, quality control, and decision-making. , ...
Breaking Biology Technology:
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Vehicle Anti-Theft System ... over the next decade to reach approximately $14.21 billion by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/22/2017)... Optimove , provider of the ... as 1-800-Flowers and AdoreMe, today announced two new ... Using Optimove,s machine learning algorithms, these features allow ... recommendations to their customers based not just on ... intent drawn from a complex web of data ...
Breaking Biology News(10 mins):